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CD4 deficit and tuberculosis risk persist with delayed
antiretroviral therapy: 5-year data from CIPRA HT-001
S. E. Collins, M. A. Jean Juste, S. P. Koenig, R. Secours, O. Ocheretina, D. Bernard, C. Riviere, M. 
Calnan, A. Dunning, S. M. Hurtado R ´ua, W. D. Johnson Jr, J. W. Pape, D. W. Fitzgerald, P. Severe
S E T T I NG : Port-au-Prince, Haiti.
OB J E C T I V E : To determine long-term effects of early vs.
delayed initiation of antiretroviral therapy (ART) on
immune recovery and tuberculosis (TB) risk in human
immunodeficiency virus (HIV) infected individuals.
D E S I GN : Open-label randomized controlled trial of
immediate ART in HIV-infected adults with CD4 counts
between 200 and 350 cells/mm3 vs. deferring ART until
the CD4 count was ,200 cells/mm3. The primary
comparisons were CD4 counts over time and risk for
incident TB, with 5 years of follow-up.
R E SU LT S : A total of 816 participants were enrolled,
with 408 in each treatment arm. The early treatment
group started ART within 2 weeks, while the deferred
treatment group started ART a median of 1.3 years after
enrollment. After 5 years, the mean CD4 count in the
early treatment group was significantly higher than in
the deferred treatment group (496 cells/mm3, 95%
confidence interval [CI] 477–515 vs. 373 cells/mm3,
95%CI 357–389; P, 0.0001). TB risk was higher in the
deferred treatment group (unadjusted HR 2.41, 95%CI
1.56–3.74; P , 0.0001) and strongly correlated with
lower CD4 counts in time-dependent multivariate
analysis.
CON C L U S I ON : Delays in ART initiation for HIV-
infected adults with CD4 counts of 200–350 cells/mm3
can result in long-term immune dysfunction and
persistent increased risk for TB.
K E Y WO R D S : human immunodeficiency virus; TB
incidence; CD4 lymphocyte count; HIV-TB; ART
FOR HUMAN IMMUNODEFICIENCY VIRUS
(HIV) infected patients with CD4 counts ,350 cells/
mm3, early initiation of antiretroviral therapy (ART)
improves survival, reduces the risk of HIV transmis-
sion, and prevents opportunistic infections.1–4 The
randomized Comprehensive Program for Research in
AIDS (CIPRA) HT-001 trial in Haiti demonstrated
that starting ARTwith a CD4 count between 200 and
350 cells/mm3 reduced mortality by 75% compared to
delaying ART until the CD4 count was ,200 cells/
mm3 or an acquired immune-deficiency syndrome
(AIDS) defining illness occurred, with the majority of
deaths occurring before initiation of ART.5 Based on
accumulated evidence from this trial and others, the
World Health Organization (WHO) revised their
guidelines in 2010, raising the CD4 threshold for
ART initiation to6350 cells/mm3, and again in 2013
to6500 cells/mm.3,6,7
It is not known if and for how long after ART
initiation patients who delay therapy have an immune
deficit and increased risk of tuberculosis (TB).
Observational studies suggest that individuals with
low CD4 counts at ART initiation have impaired
immunologic recovery on therapy, and low CD4
counts are the strongest mediator of TB risk.8–12 To
determine the effect of early ART on CD4 recovery
and TB risk, we conducted a study of the randomized
controlled CIPRA HT-001 cohort of HIV-infected
adults who received early vs. deferred ART. The
primary comparisons were CD4 count and risk of
incident TB over 5 years of follow-up.
STUDY POPULATION AND METHODS
Design and setting
CIPRA HT-001 was an open-label randomized
controlled trial conducted at the Center of the Haitian
Group for the Study of Kaposi’s Sarcoma andSEC and MAJJ contributed equally to this article.
Opportunistic Infections (GHESKIO) in Port-au-
Prince, Haiti, and was approved by the institutional
review boards at GHESKIO and Weill Cornell
Medical College, New York, NY, USA. All partici-
pants provided written informed consent.
Between August 2005 and July 2008, HIV-infected
participants aged 718 years, with a CD4 count
between 200 and 350 cells/mm3, no history of an
AIDS-defining illness (WHO Stage 4), and no prior
ART were enrolled.13 Pulmonary TB was not an
exclusion criterion. Participants were randomly
assigned to initiate ARTwithin 2 weeks of enrollment
(early treatment group), when their CD4 count was
,200 cells/mm3, or when they developed an AIDS-
defining illness (deferred treatment group). In June
2009, a scheduled interim analysis showed a survival
benefit for early ART, and the Data Safety and
Monitoring Board (DSMB) recommended that all
participants start ARTwith continued follow-up. The
2009 analysis and details on study design have been
reported previously.5
In the present study, we extended follow-up until 1
January 2012 and examined the effect of early ART
on CD4 counts and incident TB for 5 years after
randomization.
Study intervention
Participants in both groups were seen monthly by a
clinician and received an identical package of services
provided to all HIV-infected patients at GHESKIO,
including prophylaxis with trimethoprim-sulfameth-
oxazole, nutritional support and adherence counsel-
ing.14–17 Enrollees were screened for latent
tuberculous infection (LTBI) and active TB using a
purified protein derivative (PPD) skin test, chest X-
ray (CXR) and three sputum smears for acid-fast
bacilli (AFB) and mycobacterial culture. Participants
with a positive PPD (75 mm) were prescribed
isoniazid (INH) daily for 12 months.18
ART was initiated with lamivudine, zidovudine
and efavirenz, with substitutions as previously
described.5 Participants in the deferred treatment
group who had not met the study criteria for
initiating ART by June 2009 were started on ART
at the recommendation of the DSMB. Monthly
clinician visits, laboratory follow-up and data collec-
tion continued with both groups on ART until 1
January 2012.
Laboratory measurements
CD4 counts were performed at enrollment and
repeated every 6 months. Routine laboratory moni-
toring included complete blood count, aspartate
transaminase (serum glutamic oxaloacetic transami-
nase), alanine aminotransferase (serum glutamic
pyruvic transaminase) and creatinine.5
For diagnosis of TB, early morning sputum samples
smears were collected and prepared using a modified
Ziehl-Neelsen stain and examined with light micros-
copy. Samples underwent culture for Mycobacterium
tuberculosis using the BACTEC MGIT 960 system
(BD, Franklin Lakes, NJ, USA).19
Tuberculosis definitions
Incident TB was the primary clinical end-point.
Participants with symptoms suggestive of TB were
screened using CXR and three sputum samples for
AFB smear and mycobacterial culture.20 For suspect-
ed extra-pulmonary TB, a biopsy with AFB smear,
mycobacterial culture, and histopathology was per-
formed at the discretion of the study physician.
We used the TB case definition of the American
Thoracic Society as described in previous reports.21,22
For diagnosis, the required criteria were symptoms of
active TB, including fever, night sweats, weight loss,
cough, dyspnea, hemoptysis, or lymphadenopathy
and AFB on sputum smear, a positive culture for M.
tuberculosis, or histopathological findings consistent
with mycobacterial disease. For cases with negative
AFB smear, culture and histopathology, we required a
CXR highly suggestive of active TB and clinical
response to anti-tuberculosis treatment. Cases were
defined as microbiologically confirmed if AFB smear
or M. tuberculosis culture was positive.23
Patients with active TB were treated using directly
observed therapy with daily rifampin (R), isoniazid
(H), ethambutol (E), and pyrazinamide (Z) for 2
months, followed by daily RH for 4 months. Patients
who were retreated due to recurrence, treatment
failure, or default with drug-susceptible M. tubercu-
losis received streptomycin plus RHEZ.22,23 Patients
with drug-resistant TB were treated according to
WHO guidelines.24
Statistical analysis
Clinical and laboratory information were entered
electronically in Haiti, managed by Frontier Science
and Technology Research Foundation and exported
into SAS (Statistical Analysis System, Cary, NC, USA)
for analysis. Analyses were based on intention to
treat.
Mean CD4 counts and 95% confidence intervals
(CIs) were plotted over 24-week intervals for each
treatment group, starting from randomization and
separately from initiation of ART. If a participant had
more than one CD4 measurement over a 24-week
period, the lower value was incorporated. Multiple
imputations were used for missing data. The most
conservative models using weighted averages are
reported. Generalized estimating equations (GEE)
were used to compare mean CD4 counts and the rate
of change in CD4 counts of the two treatment groups.
For analysis of time to occurrence of incident TB,
we excluded participants with active TB at enroll-
ment. Primary data analysis was conducted from the
time of randomization and a secondary analysis from
the time of ART initiation. The outcome of interest
was TB diagnosis. Participants were censored on the
date they were lost to follow-up, died, or on 1 January
2012. The probability of TB-free survival was
calculated using Kaplan-Meier survival methods,
and differences were evaluated using the log-rank
test.25 Incidence rates were compared using Fisher’s
exact test.
We examined previously reported predictors of TB,
including time-independent variables (age at random-
ization, sex, education, income, PPD status, history of
TB) and time-dependent variables (CD4 count, body
mass index [BMI]) using univariate Cox proportional
hazards regression models to estimate the risk of TB
as hazard ratios (HRs) with 95%CI from the time of
enrollment.11,26 Variables with P 6 0.05 in univar-
iate analysis were retained in multivariate models. We
hypothesize that the CD4 count lies on the causal
pathway between ART and TB risk; we therefore
analyzed models with and without treatment group
as a predictor variable. Two-sided tests were adopted
for all statistical inferences.
RESULTS
Study participants
Of the 1066 subjects screened, 816 were enrolled
between August 2005 and July 2008. The median age
was 40 years; 470 (58%) were women, and the
median CD4 count was 281 cells/mm3. Forty-three
had TB at randomization, 28 (7%) in the early
treatment group and 15 (4%) in the deferred
treatment group (P ¼ 0.042). The proportion of
participants with a history of TB and those with a
positive PPD were balanced between the groups
(Table 1).
Status at time of analysis
Data were collected until 1 January 2012. The
median follow-up was 4.4 years (interquartile range
[IQR] 3.5–5.0, 1531 person-years [py]) in the early
treatment arm and 3.9 years (IQR 2.8–4.7, 1412 py)
in the deferred treatment arm.
At the time of analysis, of 408 participants in the
early treatment arm, 23 (6%) had died, 30 (7%) were
lost to follow-up, and 355 (87%) remained in care.
Of the 408 participants in the deferred treatment arm,
41 (10%) had died, 39 (10%) were lost to follow-up,
4 (1%) declined ART but remained in care, and 325
(80%) remained in care and on ART (Figure 1).
In the deferred treatment arm, 351 (86%) initiated
ART a median of 1.3 years (IQR 1–2.1) after
randomization. The median follow-up on ART was
2.5 years (IQR 2.3–3.3). After starting ART, 18 of
351 (5%) died, 9 (3%) were lost, and 324 (93%)
remained in care.
CD4 count recovery
Using GEE analysis, the mean CD4 count of the early
treatment group was significantly higher over 5 years
than that of the deferred treatment group (P ,
0.0001). At the time of randomization, the mean CD4
counts were the same (early treatment group, 262
cells/mm3, 95%CI 258–266; deferred treatment
group, 264 cells/mm3, 95%CI 259–267). At 5 years,
the mean CD4 count of the early treatment group
reached 496 cells/mm3 (95%CI 476–515), while that
of the deferred treatment group reached 373 cells/
mm3 (95%CI 357–389) (Figure 2). Multiple imputa-
tions for missing data did not significantly alter the
results of this or subsequent analyses.
Using GEE analysis, the mean CD4 count of the
early treatment group was significantly higher from
the time of ART initiation through 3 years of follow-
up on ART (P, 0.0001). In the early treatment group,
the mean CD4 count rose from a baseline value of 262
cells/mm3 to 483 cells/mm3 (95%CI 464–503) after 3
years of ART (Figure 3). In the 351 deferred treatment
group participants who started ART, the mean CD4
count rose from 186 cells/mm3 (95%CI 179–193) to
Table 1 Baseline characteristics of the study participants at
randomization
Characteristics
Early
treatment
group
n (%)
Deferred
treatment
group
n (%)
Total 408* 408*
Age, years, median [IQR] 40 [34 46] 39 [32 47]
Female sex 241 (59) 229 (56)
Education level
No school 133 (33) 120 (29)
Primary school 122 (30) 124 (30)
Secondary school or more 153 (38) 164 (40)
Annual income ,5000
HTG/year (,US$129/year) 259 (63) 254 (62)
Living with spouse or
partner 177 (43) 164 (40)
HIV clinical stage†
Stage 1 137 (36) 123 (31)
Stage 2 192 (51) 221 (56)
Stage 3 51 (13) 49 (12)
Stage 4 0 0
PPD positive 99 (24) 118 (29)
History of TB 52 (13) 50 (12)
Active pulmonary TB‡ 28 (7) 15 (4)
CD4 count, cells/mm3,
median [IQR] 280 [250 305] 282 [250 310]
BMI, kg/m2, median [IQR] 21.3 [19.6 23.7] 21 [19.2 23.4]
Hemoglobin, g/dl, median
[IQR] 11.5 [10.3 12.5] 11.4 [10.3 12.5]
* There is no significant difference in any characteristics when patients with
baseline TB were excluded.
† The clinical stage of HIV was assessed according to the World Health
Organization staging system that ranges from clinical stage 1 (no symptoms)
to clinical stage 4 (AIDS).
‡ There was no significant difference in any characteristics when patients with
baseline TB were excluded.
IQR ¼ interquartile range; HTG ¼ Haitian Gourde; HIV ¼ human immunode
ficiency virus; PPD¼purified protein derivative; TB¼ tuberculosis; BMI¼body
mass index; AIDS¼ acquired immune deficiency syndrome.



delayed ART initiation for an average of 1.3 years
had a lower mean CD4 count over 5 years of follow-
up than participants who started ART immediately.
The difference between the mean CD4 counts of the
treatment groups was 123 cells/mm3 after 5 years.
The TB incidence was 2.5 times higher in the deferred
treatment group and correlated with lower CD4
counts. The study demonstrates that short delays in
ART initiation can result in long-term immune
dysfunction and increased risk of TB.
Our findings are consistent with observational
cohorts in which the CD4 count at ART initiation
predicts the degree of immune recovery.8,27–29 More
than 75% of participants in our early treatment
group achieved a CD4 count .500 cells/mm3 by 5
years. When CD4 counts are maintained above 500
cells/mm3, mortality rates in HIV-infected individuals
can approach those of the general population.30,31 In
contrast, ,25% of the deferred treatment group
reached a CD4 count .500 cells/mm3.
Early initiation of ART is cost-effective in devel-
oping countries.32–34 Our previous cost-effectiveness
analysis of the CIPRA HT-001 trial did not account
for the long-term impact of delayed ART on TB
risk.34 The benefit of early ART will therefore likely
be greater than previously estimated. In our multi-
variate analysis, lower CD4 counts were an indepen-
dent risk factor for TB, suggesting a causal
relationship consistent with data from South Afri-
ca.12,35 These studies did not report impaired immune
recovery in patients with lower CD4 counts, a finding
we believe underlies the elevated TB risk in our
deferred treatment participants.
PPD status was not an independent risk factor for
incident TB and did not modify the effect of early
ARTon incident TB. Participants were enrolled when
their CD4 counts were ,350 cells/mm3, and as a
consequence already had some immune deficit.
Partial anergy may explain why only 25% of the
cohort was PPD-positive, when data from Haiti
suggest that 60% of the population has LTBI.
Furthermore, all the participants who tested PPD-
positive received INH prophylaxis, which can reduce
the incidence of TB by 75%.18,21 The net effect was
that PPD status was a poor predictor of incident TB in
our cohort.
CONCLUSION
Relatively short delays in ART initiation for HIV-
infected adults with a CD4 count of 200–350 cells/
mm3 can result in long-term immune dysfunction and
increased risk of TB.
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Table 2 Predictors of incident tuberculosis from the time of enrollment: univariate and multivariate Cox regression analyses
Variable
Univariate Multivariate model 1 Multivariate model 2
HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value
Baseline HIV clinical stage*
Stage 1 1.00 (reference) 1.00 (reference) 1.00 (reference)
Stage 2 1.49 (0.91 2.46) 0.1159 1.28 (0.77 2.13) 0.3450 1.24 (0.74 2.06) 0.4120
Stage 3 2.62 (1.43 4.80) 0.0018 2.13 (1.15 3.94) 0.016 2.13 (1.15 3.94) 0.0159
CD4 count (per 50 cell/mm3 decrease) 1.37 (1.24 1.52) ,0.0001 1.28 (1.15 1.41) ,0.0001 1.24 (1.11 1.38) ,0.0001
BMI (per 1 unit decrease) 1.20 (1.13 1.27) ,0.0001 1.16 (1.09 1.23) ,0.0001 1.16 (1.09 1.24) ,0.0001
Treatment group
Early 1.00 (reference) 1.00 (reference)
Deferred 2.41 (1.56 3.74) ,0.0001 1.59 (1.01 2.52) 0.0471
Age at enrollment 0.98 (0.96 1.00) 0.0535
Sex (female vs. male) 0.87 (0.58 1.31) 0.4982
History of TB† 2.25 (1.39 3.62) 0.0009
PPD positive 1.27 (0.83 1.95) 0.2781
Annual income ,5000 HTG (US$129) 1.04 (0.94 1.15) 0.4707
* The clinical stage of HIV was assessed according to theWorld Health Organization staging system that ranges from clinical stage 1 (no symptoms) to clinical stage
4 (AIDS).
† As there was a high degree of correlation between history of TB and HIV clinical stage 3, only HIV clinical stage was used in multivariate models.
HR¼hazard ratio; CI¼confidence interval; HIV¼human immunodeficiency virus; BMI¼body mass index; TB¼ tuberculosis; PPD¼purified protein derivative; HTG
¼ Haitian Gourde; AIDS¼ acquired immune deficiency syndrome.
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